Source link : https://www.newshealth.biz/health-news/second-malignancy-risk-with-car-t-cell-therapy-on-par-with-other-treatments/
CAR T-cell therapy carried a risk of second primary malignancy (SPM) that was no worse than that of other standard-of-care (SOC) cancer therapies, according to a systematic literature review and meta-analysis. The analysis showed a 5.8% rate of SPM among 5,517 patients with a median follow-up of 21.7 months. The rate did not vary according […]
Author : News Health
Publish date : 2024-09-11 21:41:27
Copyright for syndicated content belongs to the linked Source.
